GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Unicycive Therapeutics Inc (NAS:UNCY) » Definitions » 5-Year Yield-on-Cost %

UNCY (Unicycive Therapeutics) 5-Year Yield-on-Cost % : 0.00 (As of Apr. 10, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Unicycive Therapeutics 5-Year Yield-on-Cost %?

Unicycive Therapeutics's yield on cost for the quarter that ended in Dec. 2024 was 0.00.


The historical rank and industry rank for Unicycive Therapeutics's 5-Year Yield-on-Cost % or its related term are showing as below:



UNCY's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.785
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Unicycive Therapeutics's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, Unicycive Therapeutics's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Unicycive Therapeutics's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Unicycive Therapeutics's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Unicycive Therapeutics's 5-Year Yield-on-Cost % falls into.


;
;

Unicycive Therapeutics 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Unicycive Therapeutics is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Unicycive Therapeutics  (NAS:UNCY) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Unicycive Therapeutics 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Unicycive Therapeutics's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Unicycive Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
4300 El Camino Real, Suite 210, Los Altos, CA, USA, 94022
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.
Executives
Sandeep Laumas director 8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615
John L Ryan director C/O KADMON HOLDINGS, LLC, 450 E. 29TH STREET, NEW YORK NY 10016
Sara Kenkare-mitra director C/O ALECTOR, INC, 131 OYSTER POINT BLVD, SUITE 600, SOUTH SAN FRANCISCO CA 94080
Gaurav Aggarwal director C/O PANORAMA CAPITAL, 2440 SAND HILL ROAD, SUITE 302, MENLO PARK CA 94025
Douglas Jermasek other: EVP of Corporate Strategy 4300 EL CAMINO REAL, SUITE 210, LOS ALTOS CA 94022
Brigitte Schiller director UNICYCIVE THERAPEUTICS, INC., 5150 EL CAMINO REAL, SUITE A-32, LOS ALTOS CA 94022
John Townsend officer: Chief Financial Officer 15150 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128
Pramod Gupta officer: EVP, Pharmaceuticals and BD UNICYCIVE THERAPEUTICS, INC., 5150 EL CAMINO REAL, SUITE A-32, LOS ALTOS CA 94022
Shalabh K. Gupta director, officer: CEO UNICYCIVE THERAPEUTICS, INC., 5150 EL CAMINO REAL, SUITE A-32, LOS ALTOS CA 94022

Unicycive Therapeutics Headlines

From GuruFocus